PDCD1 and neoplasm: The effects of anti-PD-1 monotherapy were evaluated and displayed that the combination of PKM2-shRNA and PD-1/PD-L1 blockade had the best antitumor efficacy, resulting in smaller tumor size and lighter tumor weight, followed by PKM2 knockdown and anti-PD-1 therapy alone (Fig. 7a–c).